Cover Image
市場調查報告書

真性多血症:開發中產品分析

Polycythemia Vera - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 192784
出版日期 內容資訊 英文 66 Pages
訂單完成後即時交付
價格
Back to Top
真性多血症:開發中產品分析 Polycythemia Vera - Pipeline Review, H2 2017
出版日期: 2017年08月22日 內容資訊: 英文 66 Pages
簡介

真性多血症(PV)是幹細胞異常的一種疾病,特徵是全身增生性(panhyperplastic)、惡性、腫瘤性骨髓疾病。主要症狀有疼痛和頭痛、暈眩、倦怠感、過度發汗等。此外也有風險隨年齡增加而增大的趨勢。主要治療藥有甲醇烷基化藥等。

本報告提供全球各國治療真性多血症(真性多血症)所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

真性多血症概要

治療藥的開發

  • 真性多血症開發中產品:概要
  • 真性多血症開發中產品:比較分析

各企業開發中的真性多血症治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

真性多血症治療藥:開發中的產品一覽(各企業)

真性多血症開發治療藥的企業

  • ANP Technologies, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Galena Biopharma, Inc.
  • Gilead Sciences, Inc.
  • Italfarmaco S.p.A.
  • Karus Therapeutics Limited
  • miRagen Therapeutics, Inc.
  • Nerviano Medical Sciences S.r.l.
  • Novartis AG
  • PharmaEssentia Corporation
  • Teva Pharmaceutical Industries Ltd.

真性多血症:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

真性多血症治療藥:暫停開發的產品

真性多血症治療藥:中止開發的產品

真性多血症相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9654IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycythemia Vera - Pipeline Review, H2 2017, provides an overview of the Polycythemia Vera (Oncology) pipeline landscape.

Polycythemia Vera (PV) is a stem cell disorder characterized as a panhyperplastic, malignant and neoplastic marrow disorder. Symptoms include itchiness, headache, dizziness, weakness and excessive sweating. The risk of polycythemia vera increases with age. Treatment includes alkylating agents.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycythemia Vera - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Polycythemia Vera (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycythemia Vera (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 3, 3 and 2 respectively.

Polycythemia Vera (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Polycythemia Vera (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Polycythemia Vera (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Polycythemia Vera (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Polycythemia Vera (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Polycythemia Vera (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Polycythemia Vera (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Polycythemia Vera (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Polycythemia Vera - Overview
  • Polycythemia Vera - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Polycythemia Vera - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Polycythemia Vera - Companies Involved in Therapeutics Development
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd
    • Galena Biopharma Inc
    • Gilead Sciences Inc
    • Italfarmaco SpA
    • Nerviano Medical Sciences Srl
    • PharmaEssentia Corp
  • Polycythemia Vera - Drug Profiles
    • anagrelide hydrochloride CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dasatinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • givinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • idasanutlin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • idelalisib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-009 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-012 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NMSP-113 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • peginterferon alfa-2a - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ropeginterferon alfa-2b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Polycythemia Vera - Dormant Projects
  • Polycythemia Vera - Discontinued Products
  • Polycythemia Vera - Product Development Milestones
    • Featured News & Press Releases
      • Jun 25, 2017: AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera from 3 abstracts presented at the 22nd Congress of the European Hematology Association (EHA) in Madrid
      • Mar 14, 2017: AOP Orphan Pharmaceuticals announces start of EMA marketing authorization application procedure for Ropeginterferon alfa-2b in Polycythemia Vera
      • Dec 05, 2016: AOP Orphan and PharmaEssentia Announce Pivotal Phase III results for Ropeginterferon alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2016
      • Nov 28, 2016: PharmaEssentia Announces Phase III PROUD-PV Study Results to be Presented at ASH Annual Meeting Oral Presentation
      • Sep 12, 2016: Galena Biopharma Expands GALE-401 Intellectual Property Protection with Patent Issuance in Japan
      • May 09, 2016: Merganser Biotech Announces Issuance of U.S. Patent 9,315,545 Covering Development Compound M012
      • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
      • Dec 08, 2015: Galena Biopharma Presents Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition
      • Nov 06, 2015: Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology Annual Meeting and Exposition
      • Mar 05, 2015: AOP Orphan Pharmaceuticals announces progress of pivotal phase III trial PROUD-PV applying Ropeginterferon alfa 2b, a novel, long-acting, mono-pegylated Interferon for treatment of Polycythemia Vera
      • Nov 18, 2014: Galena Biopharma Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial
      • Oct 10, 2013: AOP Orphan Pharmaceuticals Announces Progress of Pivotal Phase III Trial PROUD-PV of Novel Mono-Pegylated Interferon Alpha 2b for the Treatment of Polycythemia Vera
      • Dec 10, 2012: AOP Orphan Pharma Reports Positive Phase II Data Of New Mono-pegylated Interferon Alpha 2b For Treatment Of Polycythemia Vera
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Polycythemia Vera, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Polycythemia Vera - Pipeline by Bristol-Myers Squibb Company, H2 2017
  • Polycythemia Vera - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Polycythemia Vera - Pipeline by Galena Biopharma Inc, H2 2017
  • Polycythemia Vera - Pipeline by Gilead Sciences Inc, H2 2017
  • Polycythemia Vera - Pipeline by Italfarmaco SpA, H2 2017
  • Polycythemia Vera - Pipeline by Nerviano Medical Sciences Srl, H2 2017
  • Polycythemia Vera - Pipeline by PharmaEssentia Corp, H2 2017
  • Polycythemia Vera - Dormant Projects, H2 2017
  • Polycythemia Vera - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Polycythemia Vera, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top